GSK Submits Shingrix Regulatory Application in Japan for Adults 18 and Older
28 June 2022 - 4:49PM
Dow Jones News
By Anthony O. Goriainoff
GSK PLC said Tuesday that Japan's Ministry of Health, Labour and
Welfare has accepted its regulatory application for its
shingles-prevention treatment, Shingrix, so that it is used in
adults age 18 and older who are at increased risk.
The U.K. pharmaceutical company, formerly known as
GlaxoSmithKline, said Shingrix has already been approved in the
country for adults age 50 and older.
The company said Shingrix's application was based on six
clinical trials in patients 18 and older who had undergone recent
blood-forming cells (stem cell)transplantation, kidney transplant,
or have blood cancer, solid tumors or HIV.
"Shingrix is also recommended in the U.S. by the U.S. Centers
for Disease Control and Prevention's Advisory Committee on
Immunization Practices as the preferred vaccine for the prevention
of shingles and related complications for immunocompetent adults
aged 50 years and older," the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 28, 2022 02:34 ET (06:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
